Cartalax
Also known as: Peptídeo articular
Molecular Identifiers
Overview
Bioregulatory tripeptide (Ala-Glu-Asp) developed by Professor Vladimir Khavinson for joint and cartilage health support. With a molecular weight of 333.29 Da, it acts on gene expression regulation of cartilaginous tissue, promoting chondroprotection and maintenance of joint integrity.
AED Ala-Glu-Asp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Healing & Recovery
Mechanism of Action
- Regulation of gene expression in cartilaginous tissue
- Chondroprotection and cartilage integrity support
- Stimulation of proteoglycan and type II collagen synthesis
- Modulation of articular inflammatory processes
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day |
| Frequency | Once daily |
| Timing | Morning, preferably fasting |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Presentations & Preparation
Vials of Cartalax found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Cartalax.
Related Peptides
ARA-290
2-4 mg per injection · Once daily
BPC-157
250-500 mcg per injection · 1-2 times daily
GHK-Cu
1-3 mg per injection · Once daily or every other day
LL-37
50-200 mcg per injection · Once daily
MGF
200-400 mcg per injection · Once daily (MGF) or 2-3 times per week (PEG-MGF)
TB-500
2-5 mg per injection · Twice per week